Lexanopadol

Lexanopadol
Clinical data
Other names	GRT-6006; GRT6006; GRT-13106-G; GRT-13106G; GRT13106G
Routes of; administration	Oral
Drug class	μ-Opioid receptor agonist; Nociceptin receptor agonist; Analgesic
ATC code	None;
Identifiers
	IUPAC name 6-fluoro-N-methyl-1'-phenylspiro[4,9-dihydro-3H-pyrano[3,4-b]indole-1,4'-cyclohexane]-1'-amine;
CAS Number	1357348-09-4;
PubChem CID	24798598;
ChemSpider	68007022;
UNII	DZ4NDW1LZX;
KEGG	D11760;
ChEMBL	ChEMBL3909973;
Chemical and physical data
Formula	C23H25FN2O
Molar mass	364.464 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNC1(CCC2(CC1)C3=C(CCO2)C4=C(N3)C=CC(=C4)F)C5=CC=CC=C5;
	InChI InChI=1S/C23H25FN2O/c1-25-22(16-5-3-2-4-6-16)10-12-23(13-11-22)21-18(9-14-27-23)19-15-17(24)7-8-20(19)26-21/h2-8,15,25-26H,9-14H2,1H3; Key:AMXGKMSRYLZAEO-UHFFFAOYSA-N;

Lexanopadol (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), also known by its developmental code name GRT-6006, is an opioid receptor modulator which was under development for the treatment of pain. It is taken orally. The drug acts as a dual agonist of the μ-opioid receptor and nociceptin receptor. It is thought that the combination of these activities may confer enhanced analgesic efficacy. Lexanopadol was under development by Grünenthal. It reached phase 1 or 2 clinical trials prior to the discontinuation of its development, with no further development reported by 2016. The drug was a follow-on compound to cebranopadol (GRT-6005).